PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) has been notified of an unsolicited “mini-tender offer” by TRC Capital Investment Corporation to purchase up to 1,000,000 shares of Zoetis common stock, representing approximately 0.21% of the outstanding shares of Zoetis common stock.

TRC’s offer price of $109.00 per share is approximately 4.9% lower than the $114.61 closing price per share of Zoetis common stock on April 3, 2020, the last trading day before the commencement of the offer, and approximately 14.5% below the $127.45 closing price per share of Zoetis common stock on April 16, 2020, the last trading day before the date of this press release.

TRC has made similar, unsolicited mini-tender offers for shares of other publicly traded companies. Zoetis does not endorse TRC’s unsolicited mini-tender offer and is not associated in any way with TRC, its mini-tender offer or its mini-tender offer documents.

About Zoetis

Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees. For more information, visit www.zoetis.com.